Drug intelligence / Profile preview

tafoxiparin + oxytocin

Development stage
Phase 2
Lead developer
Dilafor
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

**Tafoxiparin + oxytocin** is an investigational combination used in obstetric care, primarily studied for protracted or slow-progressing labor. **Tafoxiparin** is a synthetic, depolymerized form of heparin with negligible anticoagulant activity, developed to promote cervical ripening and enhance the labor process. **Oxytocin** is a well-established peptide hormone and uterotonic agent that induces uterine contractions. The combination is administered to augment uterine contractility and support cervical changes, aiming to reduce labor complications such as prolonged or arrested labor. Phase II clinical trials have shown that the combination may reduce labor time and improve cervical ripening, especially among women requiring induction or experiencing slow progression, though primary efficacy endpoints in larger studies were not met. The combination has demonstrated a favorable safety profile in mothers and infants.

02

Targets

Cervical extracellular matrix glycosaminoglycanOxytocin receptor

Beyond the preview

Go deeper on tafoxiparin + oxytocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tafoxiparin + oxytocin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call